Article
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.
The Journal of pathology - 1 Sept 2007
Tomlinson D C, Baldo O, Harnden P, Knowles M A
Abstract excerpt
FGFR3 is frequently activated by mutation in urothelial carcinoma (UC) and represents a potential target for therapy. In multiple myeloma, both over-expression and mutation of FGFR3 contribute to tumour development. To define the population of UC patients who may benefit from FGFR-targeted therapy, we assessed both mutation and receptor over-expression in primary UCs from a population of new patients. Manual or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.